<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39436613</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2509-8020</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of patient-reported outcomes</Title><ISOAbbreviation>J Patient Rep Outcomes</ISOAbbreviation></Journal><ArticleTitle>Associations between symptom-based long COVID clusters and long-term quality of life, work and daily activities among individuals testing positive for SARS-CoV-2 at a national retail pharmacy.</ArticleTitle><Pagination><StartPage>122</StartPage><MedlinePgn>122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41687-024-00797-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Evidence on long COVID symptom clustering patterns among patients with COVID-19 is limited. We summarized long COVID symptoms in clusters defined by number of symptoms co-occurring together, and we assessed Health-Related Quality of Life (HQRoL), Work Productivity and Activity Impairment (WPAI) outcomes across these clusters over time. We assessed associations between the clusters and BNT162b2 vaccination status.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective longitudinal patient-reported outcomes (PRO) study recruited laboratory-confirmed symptomatic COVID-19 patients seeking testing from a national retail pharmacy. Long COVID-19 symptoms were self-reported by participants at 4-week, 3-month and 6-month surveys. Patient classes identified via latent class analysis (LCA) with long COVID-19 symptoms were simplified into clusters based on number of symptoms. HRQoL and WPAI outcomes were collected using EQ-ED-5L and WPAI: GH questionnaires. Mixed models for repeated measures analyses were conducted to examine associations between exposure groups and outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 328 participants that were segmented into three groups of long COVID-19 symptoms based on LCA and then simplified by the number of symptoms (Cluster 1 low, &lt;2; Cluster 2 moderate, 2-6; and Cluster 3 high, &gt;6 symptoms). The number of long COVID-19 symptoms was negatively associated with HRQoL and WPAI, whereby participants with high symptom burden (&gt;6 symptoms) had the lowest HRQoL and WPAI scores assessed by absenteeism, presenteeism, work productivity loss, activity impairment, and hours worked metrics. Compared with those unvaccinated and not up-to-date with COVID-19 vaccination, subjects boosted with BNT162b2 consistently reported less symptom burden during the follow-up, regardless of their symptom-based cluster.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Three distinct patient clusters based on frequency of long COVID symptoms experienced different HRQoL and WPAI outcomes over 6 months. The cluster with more concomitant symptoms experienced greater burden than the others. Participants up-to-date with BNT162b2 reported lower symptom burden across all clusters and timeframes.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov NCT05160636.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Fusco</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0079-7331</Identifier><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA. Manuela.difusco@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappelleri</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yehoshua</LastName><ForeName>Alon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Kelly J Thomas</ForeName><Initials>KJT</Initials><AffiliationInfo><Affiliation>CVS Health, Woonsocket, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Mary B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Kristen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Santiago M C</ForeName><Initials>SMC</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzniak</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaowu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>CVS Health, Woonsocket, RI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05160636</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>Not applicable</GrantID><Agency>Pfizer</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Patient Rep Outcomes</MedlineTA><NlmUniqueID>101722688</NlmUniqueID><ISSNLinking>2509-8020</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="Y">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010594" MajorTopicYN="N">Pharmacies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000041" MajorTopicYN="N">Absenteeism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004526" MajorTopicYN="N">Efficiency</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">HRQoL</Keyword><Keyword MajorTopicYN="N">Humanistic</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">WPAI</Keyword><Keyword MajorTopicYN="N">long-COVID-19 symptoms</Keyword></KeywordList><CoiStatement>MDC, AY, MBA, KEA, TMP, LP, SMCL, and JCC are employed by Pfizer<sup>&#xae;</sup> Inc. and hold stock or stock options of Pfizer. XS and KJTC are employed by CVS Health<sup>&#xae;</sup> Corporation and hold stock and receive equity from CVS Health, which received funding from Pfizer in connection with the development of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39436613</ArticleId><ArticleId IdType="pmc">PMC11496399</ArticleId><ArticleId IdType="doi">10.1186/s41687-024-00797-7</ArticleId><ArticleId IdType="pii">10.1186/s41687-024-00797-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention. Long COVID basics. https://www.cdc.gov/covid/long-term-effects/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed 18 May 2024</Citation></Reference><Reference><Citation>Ford ND, Slaughter D, Edwards D, Dalton A, Perrine C, Vahratian A, Saydah S (2023) Long COVID and significant activity limitation among adults, by Age - United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb Mortal Wkly Rep 72(32):866&#x2013;870. 10.15585/mmwr.mm7232a3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, Redfield S, Austin JP, Akrami A (2021) Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38:101019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, Karamchandani U, Simms-Williams N, Cassambai S, Ardavani A (2023) The prevalence and long-term health effects of long covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine 55:101762</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21(3):133&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM (2022) The costs of long COVID. American Medical Association, JAMA Health Forum, pp e221809&#x2013;e</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Alvarez MB, Puzniak L, Tabak YP, Cappelleri JC (2023) Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron. J Patient Rep Outcomes 7(1):77. 10.1186/s41687-023-00616-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10366033</ArticleId><ArticleId IdType="pubmed">37486567</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, Peligro PJ, Casimiro M, Guerrero JJ, Gellaco MML (2022) Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine 53:101624</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T (2023) Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine 41(11):1783&#x2013;1790. 10.1016/j.vaccine.2023.02.008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Jabal KA, Dror A, Nazzal S, Glikman D, Edelstein M (2022) Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021. medRxiv. 10.1101/2022.01.05.22268800</Citation></Reference><Reference><Citation>Goldhaber NH, Kohn JN, Ogan WS, Sitapati A, Longhurst CA, Wang A, Lee S, Hong S, Horton LE (2022) Deep dive into the long haul: analysis of Symptom clusters and risk factors for Post-acute Sequelae of COVID-19 to inform Clinical Care. Int J Environ Res Public Health 19(24):16841</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9778884</ArticleId><ArticleId IdType="pubmed">36554723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, Zhang Y, Xu J, Bian J, Morozyuk D, Khullar D, Zhang Y, Nordvig AS (2023) Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med 29(1):226&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AW, Tran KC, Binka M, Janjua NZ, Sbihi H, Russell JA, Carlsten C, Levin A, Ryerson CJ (2023) Use of latent class analysis and patient reported outcome measures to identify distinct long COVID phenotypes: a longitudinal cohort study. PLoS ONE 18(6):e0286588. 10.1371/journal.pone.0286588</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10237387</ArticleId><ArticleId IdType="pubmed">37267379</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitsios GD, Blacka S, Jacobs JJ, Mirza T, Naqvi A, Gentry H, Murray C, Wang X, Golubykh K, Qurashi H (2024) Subphenotypes of self-reported symptoms and outcomes in long COVID: a prospective cohort study with latent class analysis. BMJ open 14(3):e077869</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10941166</ArticleId><ArticleId IdType="pubmed">38485476</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, DeShazo JP, Anatale-Tardiff L, Di Fusco M, Allen KE, Porter TM, Coetzer H, Lopez SM, Puzniak L, Cappelleri JC (2023) Postacute sequelae SARS-CoV-2 infection by vaccination status: a six-month latent class analysis. medRxiv. 10.1101/2023.10.20.23297332</Citation></Reference><Reference><Citation>Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Puzniak L, Alvarez MB, Tabak YP, Cappelleri JC (2022) Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients. J Patient Rep Outcomes 6:123. 10.1186/s41687-022-00528-w</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9722994</ArticleId><ArticleId IdType="pubmed">36469198</ArticleId></ArticleIdList></Reference><Reference><Citation>Our World in Data. COVID-19 vaccine doses administered by manufacturer, United States. https://ourworldindata.org/grapher/covid-vaccine-doses-by-manufacturer?country=~USA. Accessed 19 Jul 2024</Citation></Reference><Reference><Citation>EuroQol Research Foundation (2019) EQ-5D-5L User Guide, Version 3.0. https://euroqol.org/publications/user-guides Accessed 22 Aug 2023</Citation></Reference><Reference><Citation>Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4(5):353&#x2013;365</Citation><ArticleIdList><ArticleId IdType="pubmed">10146874</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly Associates (2002) WPAI Scoring. http://www.reillyassociates.net/WPAI_Scoring.html. Accessed 9 Sep 2023</Citation></Reference><Reference><Citation>Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV (2019) United States Valuation of EQ-5D-5L Health States using an International Protocol. Value Health 22(8):931&#x2013;941. 10.1016/j.jval.2019.02.009</Citation><ArticleIdList><ArticleId IdType="pubmed">31426935</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller BE, Bowen NK, Faubert SJ (2020) Latent class analysis: a guide to best practice. J Black Psychol 46(4):287&#x2013;311</Citation></Reference><Reference><Citation>Fitzmaurice GM, Laird NM, Ware JH (2011) Applied longitudinal analysis, Second edn. Wiley, Hoboken, NJ</Citation></Reference><Reference><Citation>Harrell FE (2015) Ordinal Logistic Regression. In: Regression modeling strategies: with applications to Linear models, logistic and ordinal regression, and survival analysis. Springer International Publishing, Cham, pp 311&#x2013;325</Citation></Reference><Reference><Citation>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Accessed 19 July 2024. https://www.equator-network.org/reporting-guidelines/strobe/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>